|Early Drug Development in cooperation with the Pharmaceutical Industry|
Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data.
Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
Twin Sample™ Biopsy Needle featured at AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy, June 13 – 16, 2015, Grand America Hotel, Salt Lake City, Utah
Twin Sample™ Biopsy Needle featured at AACR Annual Meeting 2015, April 18 – 22, Pennsylvania Convention Center, Philadelphia
Twin Sample™ Biopsy Needle featured at SIR 2015, Society of Interventional Radiology’s Annual Scientific Meeting, February 28 – March 5, Georgia World Congress Center, Atlanta
Twin Sample™ Biopsy Needle featured at ESUR2014, in Glasgow, October 9-11.
Twin Sample™ Biopsy Needle featured at AACR Annual Meeting 2014, April 5-9, San Diego
Epitome presents research on Warfarin dosing and INR variability at Thrombosis and Hemostasis Summit of North America (THSNA) April 10-12, 2014, Chicago, IL
Twin Sample™ is a trademark of Epitome Pharmaceuticals Limited.
Veregen® is a registered trademark of MediGene AG.